Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Poll: Transcatheter Mitral Valve Replacement in a High Surgical Risk Patient With Mitral StenosisMrs. M is an 81-year-old female patient who presents with worsening exertional dyspnea. She has a history of type 2 diabetes mellitus, heart failure with preserved ejection fraction, and prior surgical aortic valve replacement in the setting of severe symptomatic aortic stenosis.
- PRAGUE-25: What Is the Best Intervention Strategy For AFib In Obesity?Catheter ablation (CA) was superior to a combination of lifestyle modification (LFM) and antiarrhythmic drugs (AADs) in improving freedom from atrial fibrillation (AFib) at one year in patients with obesity, according to results from the PRAGUE-25 trial published in JACC.
- June AMA House of Delegates Key TakeawaysThe American Medical Association (AMA) House of Delegates met in June to discuss and vote on the latest round of proposed resolutions aimed at guiding AMA’s policies on key medical, ethical and public health issues.
- SWISS-APERO: Similar 3-Year Ischemic Risk With Amulet vs. Watchman FLXWhile there was no significant difference in ischemic risk in patients with atrial fibrillation between the Amulet and Watchman FLX devices at three years following left atrial appendage closure (LAAC), according to findings from the SWISS-APERO trial published in JACC...
- ACCEL Lite: Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEFIn this interview, Drs. Matthew Martinez and Barry Borlaug discuss “Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEF.â€